A Preliminary Assessment of Macular Function by MF-ERG in Myopic Eyes with CNV with Complete Response to Photodynamic Therapy

Abstract

Purpose

To evaluate by multifocal electroretinogram (MF-ERG) macular function before and after photodynamic therapy (PDT) in myopic eyes with choroidal neovascularization (CNV).

Patients and Methods

Ten eyes with classic subfoveal CNV due to pathologic myopia were studied with MF-ERG before and after PDT in order to evaluate the results of PDT with verteporfin. The post-treatment follow-up was 6 months.

Visual acuity testing, ophthalmic examinations, fluorescein and indocyanine green angiograms, and MF-ERG recordings were used to evaluate the results of PDT with verteporfin. The post-treatment period was 6 months.

Results

Before treatment, the electrical response densities in the foveal and perifoveal areas were apparently decreased in all patients. Six months after treatment, the mean retinal response densities in the same areas were found to be higher than before treatment.

Conclusions

MF-ERG evaluates objectively the macular function in myopic eyes with CNV. After successful PDT, the electrical activity of the foveal and parafoveal areas is higher than before treatment. This finding postulates the efficacy of PDT in the treatment of CNV.

Keywords

Verteporfin Choroidal neovascularization Myopia Photodynamic therapy Multifocal electroretinogram

Get full access to this article

View all access options for this article.

References

American Academy of Ophthalmology. Age-related macular degeneration - Preferred pattern. San Francisco: American Academy of Ophthalmology; 1998. www.aao.org/aao/newsroom/facts/amd.cfm

Cutrin

B.J.

. Myopias. Philadelphia: Harper & Row; 1985: 309–30.

Macular Photocoagulation Study Group.

Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials.

Arch Ophthalmol 1991; 109: 1109–14.

Verteporfin in Photodynamic Therapy Study Group.

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult classic choroidal neovascularization—Verteporfin in Photodynamic Therapy report 2.

Am J Ophthalmol 2001; 131: 541–60.

Yoshida

Ohno

Ohtake

Long-term visual prognosis of choroidal neovascularization in high myopia.

Ophthalmology 2001; 109: 712–9.

American Academy of Ophthalmology.

Photodynamic technology with verteporfin for age-related macular degeneration.

Ophthalmology 2000; 107: 2314–7.

Sickenberg

Schmidt-Erfurth

Miller

W.J.

A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks and idiopathic cases.

Arch Ophthalmol 2000; 118: 327–36.

Verteporfin in Photodynamic Therapy (VIP) Study Group.

Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial-VIP report 1.

Ophthalmology 2001; 108: 841–52.

Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group.

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials-TAP report 2.

Arch Ophthalmol 2001; 119: 198–207.

10.

Husain

Kramer

Kenney

A.G.

Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularisation and normal retina and choroid up to seven weeks after treatment.

Invest Ophthalmol Vis Sci 1999; 105: 2322–31.

11.

Kramer

Miller

J.W.

Michaud

Liposomal benzoporphyrin derivative verteporfin in photodynamic therapy: selective treatment of choroidal neovascularization in monkeys.

Ophthalmology 1996; 103: 427–38.

12.

Sutter

E.E.

Tran

. The field topography of ERG in man, 1. The photopic luminance response. Vision Res 1992; 32: 433–66.